Biotech · Private company
Mirati Therapeutics Inc.
Track this companyFree. Adds Mirati Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2513 recruiting or active
Pipeline programs42From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline42
- AdagrasibPhase 3 · Advanced Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- AdagrasibPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 3 · Advanced Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 3 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Enfortumab Vedotin-EjfvPhase 3 · Advanced or Metastatic Solid MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- FOLFIRI RegimenPhase 3 · Advanced Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- IpilimumabPhase 3 · Advanced or Metastatic Solid MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- mFOLFOX6 RegimenPhase 3 · Advanced Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- MRTX849Phase 3 · Advanced Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- MRTX849Phase 3 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- NivolumabPhase 3 · Advanced or Metastatic Solid MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Advanced Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Advanced or Metastatic Solid MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 3 · Carcinoma, Non-Small-Cell LungClinicalTrials.gov · fetched Nov 12, 2026
- SitravatinibPhase 3 · Advanced or Metastatic Solid MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- SitravatinibPhase 3 · Metastatic Non-Squamous Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- AdagrasibPhase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- AdagrasibPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- Adagrasib oral dose of 400 mg twice daily tabletsPhase 2 · Advanced NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- AfatinibPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- CetuximabPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- Chemotherapy: PemetrexedPhase 2 · Advanced NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- Cisplatin/CarboplatinPhase 2 · Advanced NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- DocetaxelPhase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- IrinotecanPhase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- MRTX849Phase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Advanced CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Advanced NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- AdagrasibPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- AdagrasibPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- AdagrasibPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- MRTX0902Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- MRTX849Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- nab-SirolimusPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese DescentPHASE1 · COMPLETED · started Aug 5, 2026ClinicalTrials.gov NCT07723118 · fetched Nov 12, 2026
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesPHASE2 · RECRUITING · started May 6, 2026ClinicalTrials.gov NCT07415031 · fetched Nov 12, 2026
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)PHASE3 · RECRUITING · started Apr 24, 2025ClinicalTrials.gov NCT06875310 · fetched Nov 12, 2026
- Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load TabletsPHASE1 · COMPLETED · started Feb 4, 2025ClinicalTrials.gov NCT06801418 · fetched Nov 12, 2026
- Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesPHASE2 · RECRUITING · started Aug 6, 2024ClinicalTrials.gov NCT06248606 · fetched Nov 12, 2026
- Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 1, 2024ClinicalTrials.gov NCT05853575 · fetched Nov 12, 2026
- Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung CancersPHASE1 · TERMINATED · started Jan 30, 2024ClinicalTrials.gov NCT06130254 · fetched Nov 12, 2026
- A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationPHASE1 · TERMINATED · started Dec 28, 2023ClinicalTrials.gov NCT06039384 · fetched Nov 12, 2026
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPHASE1 · RECRUITING · started Oct 18, 2023ClinicalTrials.gov NCT06026410 · fetched Nov 12, 2026
- Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)PHASE1 · TERMINATED · started Aug 7, 2023ClinicalTrials.gov NCT05840510 · fetched Nov 12, 2026
- Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer PatientsPHASE1 · WITHDRAWN · started May 3, 2023ClinicalTrials.gov NCT05634525 · fetched Nov 12, 2026
- Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabPHASE2 · WITHDRAWN · started Mar 21, 2023ClinicalTrials.gov NCT05472623 · fetched Nov 12, 2026
- A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayPHASE1 · TERMINATED · started Dec 2, 2022ClinicalTrials.gov NCT05578092 · fetched Nov 12, 2026
- Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationPHASE2 · ACTIVE_NOT_RECRUITING · started Nov 22, 2022ClinicalTrials.gov NCT05609578 · fetched Nov 12, 2026
- Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC PatientsPHASE1_PHASE2 · COMPLETED · started Aug 1, 2022ClinicalTrials.gov NCT05375994 · fetched Nov 12, 2026
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyPHASE2_PHASE3 · COMPLETED · started Jun 29, 2021ClinicalTrials.gov NCT04887870 · fetched Nov 12, 2026
- Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 24, 2021ClinicalTrials.gov NCT04793958 · fetched Nov 12, 2026
- Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 23, 2021ClinicalTrials.gov NCT04685135 · fetched Nov 12, 2026
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7PHASE2_PHASE3 · RECRUITING · started Dec 2, 2020ClinicalTrials.gov NCT04613596 · fetched Nov 12, 2026
- Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesPHASE1_PHASE2 · TERMINATED · started Jun 9, 2020ClinicalTrials.gov NCT04418661 · fetched Nov 12, 2026
- Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent RhabdomyosarcomaPHASE1 · ACTIVE_NOT_RECRUITING · started May 14, 2020ClinicalTrials.gov NCT04299113 · fetched Nov 12, 2026
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 17, 2019ClinicalTrials.gov NCT03994796 · fetched Nov 12, 2026
- Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung CancerPHASE3 · TERMINATED · started Jul 15, 2019ClinicalTrials.gov NCT03906071 · fetched Nov 12, 2026
- Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 15, 2019ClinicalTrials.gov NCT03785249 · fetched Nov 12, 2026
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.PHASE1 · ACTIVE_NOT_RECRUITING · started Aug 4, 2017ClinicalTrials.gov NCT03220477 · fetched Nov 12, 2026